Mon-Fri 9:00-18:00 CET+39 095 7211344info@vitasanlabs.com

Family · Pharmaceutical analytical standards

Stiripentol

An antiepileptic used in Dravet syndrome, a rare and severe childhood epilepsy, together with clobazam and valproate: approved in Europe in 2007 as an orphan medicine and in the United States in 2018. This family brings together the active ingredient, metabolites, labelled standards and other impurities.

Did you know?It was discovered in France in 1978 and tested on many forms of epilepsy; the turning point came in 1999, when a French study noticed it worked especially well in children with Dravet syndrome.

StiripentolGo to the active ingredient →
StiripentolActive ingredientStiripentolCat. No. P-S086-001CAS 137767-55-6
Stiripentol-d9Isotopically labelledStiripentol-d9Cat. No. P-S086-016CAS 1185239-64-8

Need a molecule you cannot find?

Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.